Lung cancer experts discuss the optimal management of CNS disease in EGFR-mutated non–small cell lung cancer.
|Videos|June 30, 2011
Dr. Kris Describes the Genetic Mutation Screening Study
Author(s)Mark G. Kris, MD, FASCO
Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study
Advertisement
Mark G. Kris, MD, chief of the Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center, describes the genetic mutation screening multicenter study that he was the lead author for and presented at the 2011 annual meeting of the American Society of Clinical Oncology.
Advertisement
Related to this article
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA approved selpercatinib for RET fusion–positive advanced solid tumors.
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5